Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9668292 | 0.98 | EPHX1 (0.50) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| Nitric Acid SCHEMBL7366281 | 0.89 | EPHX1 (0.46) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| SCHEMBL13584612 | 0.89 | EPHX1 (0.59) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| SCHEMBL29518499 | 0.89 | EPHX1 (0.59) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL13584366 | 0.87 | EPHX1 (0.57) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| SCHEMBL4100753 | 0.86 | EPHX1 (0.58) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| SCHEMBL1995869 | 0.85 | EPHX1 (0.59) | EPHX1EPHX2IDO1GAAALDH1A1 | |
| SCHEMBL4103672 | 0.85 | KMT2A (0.56) | ALDH1A1CA2MAPTNPSR1NPC1 | |
| SCHEMBL11834166 | 0.85 | GAA (0.51) | GAAALDH1A1CA2MAPTALOX15 | |
| SCHEMBL11837380 | 0.85 | NPC1 (0.42) | EPHX1EPHX2IDO1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | claimed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | claimed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | claimed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | claimed |
| CN-117062940-A | Composition and method for treating substrate | 富士胶片株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-115746855-A | Treatment liquid | 富士胶片株式会社 | 2023-03-07 | — | — | CN | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| CN-114364780-A | Treatment liquid, kit, method for producing treatment liquid, method for cleaning substrate, and method for treating substrate | 富士胶片株式会社 | 2022-04-15 | — | — | CN | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| CN-108485840-B | Cleaning formulation for removing residues on surfaces | 富士胶片电子材料美国有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-1902059-A1 | ANTIMICROBIAL BIGUANIDE METAL COMPLEXES | Smith & Nephew, PLC (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007000590-A1 | ANTIMICROBIAL BIGUANIDE METAL COMPLEXES | SMITH & NEPHEW PLC (GB) | 2007-01-04 | — | — | WO | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | EPHX1 3275/4885EPHX2 3607/4885IDO1 4081/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | EPHX1 2097/4885EPHX2 1873/4885IDO1 3912/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | EPHX1 2097/4885EPHX2 1873/4885IDO1 3912/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | EPHX1 2359/4885EPHX2 2936/4885IDO1 118/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | EPHX1 2097/4885EPHX2 1873/4885IDO1 3912/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | EPHX1 3675/4885EPHX2 3448/4885IDO1 20/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | EPHX1 3275/4885EPHX2 3607/4885IDO1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.